(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 10.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.16%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.87%.
Prothena Public Co's revenue in 2024 is $133,350,000.On average, 5 Wall Street analysts forecast PRTA's revenue for 2024 to be $7,768,904,726, with the lowest PRTA revenue forecast at $7,156,561,356, and the highest PRTA revenue forecast at $9,848,612,218. On average, 3 Wall Street analysts forecast PRTA's revenue for 2025 to be $8,991,600,543, with the lowest PRTA revenue forecast at $2,738,864,459, and the highest PRTA revenue forecast at $16,142,619,600.
In 2026, PRTA is forecast to generate $9,704,673,860 in revenue, with the lowest revenue forecast at $5,464,276,735 and the highest revenue forecast at $14,491,767,702.